IRLAB Therapeutics AB (publ)
SSE:IRLAB-A.ST
14.45 (SEK) • At close February 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SEK.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 5.678 | 61.136 | 207.782 | 0.3 | 0.026 | 0.018 | 0.109 | 0.144 | 2.88 | 0.054 |
| Cost of Revenue
| 185.81 | 172.369 | 39.091 | 1.997 | 96.229 | 74.093 | 10.128 | 49.165 | 30.669 | 13.953 |
| Gross Profit
| -180.132 | -111.233 | 168.691 | -1.697 | -96.203 | -74.075 | -10.019 | -49.021 | -27.789 | -13.899 |
| Gross Profit Ratio
| -31.725 | -1.819 | 0.812 | -5.657 | -3,700.115 | -4,115.278 | -91.917 | -340.424 | -9.649 | -257.389 |
| Reseach & Development Expenses
| 151.312 | 146.178 | 39.35 | 76.248 | 79.381 | 58.927 | 45.219 | 38.964 | 26.227 | 15.522 |
| General & Administrative Expenses
| 0 | 125.906 | 81.737 | 65.63 | 71.161 | 54.27 | 42.602 | 37.507 | 22.274 | 14.87 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| -151.312 | 125.906 | 81.737 | 65.63 | 71.161 | 54.27 | 42.602 | 37.507 | 22.274 | 14.87 |
| Other Expenses
| 186.444 | 48.339 | 34.378 | 25.828 | 24.787 | 19.645 | 12.787 | 8.69 | 5.338 | -0.34 |
| Operating Expenses
| 186.444 | 174.245 | 116.115 | 91.458 | 95.948 | 73.915 | 55.389 | 46.197 | 27.612 | 14.53 |
| Operating Income
| -180.132 | -113.109 | 52.576 | -91.458 | -95.848 | -73.897 | -54.219 | -49.199 | -27.571 | -14.476 |
| Operating Income Ratio
| -31.725 | -1.85 | 0.253 | -304.86 | -3,686.462 | -4,105.389 | -497.422 | -341.66 | -9.573 | -268.074 |
| Total Other Income Expenses Net
| 2.293 | -0.297 | -0.795 | -0.195 | -0.272 | -0.202 | -2.005 | 3.122 | -0.123 | 9.21 |
| Income Before Tax
| -177.839 | -113.406 | 51.781 | -91.653 | -96.12 | -74.099 | -56.224 | -46.077 | -27.694 | -5.266 |
| Income Before Tax Ratio
| -31.321 | -1.855 | 0.249 | -305.51 | -3,696.923 | -4,116.611 | -515.817 | -319.979 | -9.616 | -97.519 |
| Income Tax Expense
| 4.148 | 0.797 | 0.37 | 0.195 | 0.198 | 0.202 | -1.061 | -3.381 | -6.912 | -3.145 |
| Net Income
| -177.839 | -114.203 | 51.781 | -91.848 | -96.318 | -74.099 | -56.225 | -42.696 | -11.887 | 3.122 |
| Net Income Ratio
| -31.321 | -1.868 | 0.249 | -306.16 | -3,704.538 | -4,116.611 | -515.826 | -296.5 | -4.127 | 57.815 |
| EPS
| -3.43 | -2.2 | 1 | -1.93 | -2.33 | -1.9 | -1.64 | -1.66 | -0.49 | 0.13 |
| EPS Diluted
| -3.43 | -2.2 | 1 | -1.93 | -2.33 | -1.9 | -1.64 | -1.66 | -0.49 | 0.13 |
| EBITDA
| -175.816 | -108.33 | 55.625 | -89.202 | -92.99 | -72.565 | -54.931 | -45.735 | -27.254 | -5.028 |
| EBITDA Ratio
| -30.964 | -1.772 | 0.268 | -297.34 | -3,576.538 | -4,031.389 | -503.954 | -317.604 | -9.463 | -93.111 |